Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Elmer Berghorn"'
Autor:
Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The ope
Externí odkaz:
https://doaj.org/article/f0f7e77e195b4d86bb727fc6abf001f6
Autor:
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, Lionel D. Lewis, Todd M. Bauer, David F. McDermott, Michael Carducci, Christian Kollmannsberger, Brian I. Rini, Daniel Y. C. Heng, Jennifer Knox, Martin H. Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-1 (2019)
Externí odkaz:
https://doaj.org/article/cc6f96a5dbeb407780a3d357f622ecdb
Autor:
Daniel P. Petrylak, Tyler F. Stewart, Xin Gao, Elmer Berghorn, Haolan Lu, Edward Chan, Richard Gedrich, Joshua Michael Lang, Meredith McKean
Publikováno v:
Journal of Clinical Oncology. 41:TPS290-TPS290
TPS290 Background: Patients with mCRPC inevitably develop resistance to available therapies and lack curative options. In patients treated with novel hormonal agents (NHAs), mutations can develop in the ligand-binding domain (LBD) of the AR gene, som
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2a536ca63ff031ec39c5de1d5e09b2a
https://doi.org/10.1200/jco.2023.41.6_suppl.tps290
https://doi.org/10.1200/jco.2023.41.6_suppl.tps290
Autor:
Xin Gao, Howard A. Burris III, Jacqueline Vuky, Robert Dreicer, A. Oliver Sartor, Cora N. Sternberg, Ivor John Percent, Maha H. A. Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada-Terk, Sunil G. Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, S. Debbie Chirnomas, Nicholas J. Vogelzang, Daniel P. Petrylak
Publikováno v:
Journal of Clinical Oncology. 40:17-17
17 Background: ARV-110 is a first-in-class, oral PROteolysis TArgeting Chimera (PROTAC) protein degrader that selectively targets AR. Patients (pts) with mCRPC have limited treatment (tx) options due to decreasing AR dependence of tumors upon success
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d3da3d6fd6074b95b6ea82d80c4b7ea
https://doi.org/10.1200/jco.2022.40.6_suppl.017
https://doi.org/10.1200/jco.2022.40.6_suppl.017
Autor:
Lionel D. Lewis, David F. McDermott, Christian Kollmannsberger, Jennifer L. Spratlin, Marc S. Ernstoff, Michael A. Carducci, Brian I. Rini, Asim Amin, Daniel Y.C. Heng, Elmer Berghorn, Lingfeng Yang, Hans J. Hammers, Martin H. Voss, Elizabeth R. Plimack, Todd M. Bauer, Jennifer J. Knox
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc173dc612c24796154312f87f15907f
http://link.springer.com/article/10.1186/s40425-018-0420-0
http://link.springer.com/article/10.1186/s40425-018-0420-0
Autor:
Jun Shen, Ira J. Dunkel, Lia Gore, Birgit Geoerger, Alberto S. Pappo, Ofelia Cruz, Leonard S. Sender, Elmer Berghorn, Lieve Brochez, Burcin Simsek, Christophe Bergeron, Cynthia E. Herzog, Karsten Nysom
Publikováno v:
European Journal of Cancer. 86:358-363
Ipilimumab is approved for the treatment of advanced melanoma in adults; however, little information on the efficacy and safety of ipilimumab in younger patients is available.Patients aged 12 to18 years with previously treated or untreated, unresecta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec148d1a32ff2d92ad1a740cfa123e7b
https://doi.org/10.1016/j.ejca.2017.09.032
https://doi.org/10.1016/j.ejca.2017.09.032
Autor:
Seiichiro Ozono, Nobuo Shinohara, Kazunari Tanabe, Hiroshi Kitamura, Masahiro Yao, Yoshihiko Tomita, Elmer Berghorn, Mototsugu Oya, Junji Yonese, Robert J. Motzer, Go Kimura, Satoshi Fukasawa, M. Brent McHenry, Masatoshi Eto, Hirotsugu Uemura
Publikováno v:
Japanese Journal of Clinical Oncology
With >2 years of follow-up, Japanese patients from the international phase III CheckMate 025 study had a higher response rate with nivolumab versus everolimus and a favorable safety profile.
Background Nivolumab improved overall survival (OS) an
Background Nivolumab improved overall survival (OS) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa1a1a936ab55cc8b8ef371f4475f7ce
https://doi.org/10.1093/jjco/hyx049
https://doi.org/10.1093/jjco/hyx049
Autor:
Todd M. Bauer, Brian I. Rini, Asim Amin, David F. McDermott, Christian Kollmannsberger, Martin H. Voss, Jennifer L. Spratlin, Hans J. Hammers, Lionel D. Lewis, Elizabeth R. Plimack, Michael A. Carducci, Marc S. Ernstoff, Lingfeng Yang, Jennifer J. Knox, Daniel Y.C. Heng, Elmer Berghorn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-1 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Combination treatment with immune checkpoint inhibitors and antiangiogenic drugs has shown encouraging preliminary antitumor activity across various tumor types including advanced or metastatic renal cell carcinoma (aRCC). The open-label, parallel-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b919236b9d292035fb1e8d4095767d
https://doi.org/10.1186/s40425-019-0559-3
https://doi.org/10.1186/s40425-019-0559-3
Autor:
Fiona Taylor, Homa Dastani, Elmer Berghorn, Justin Doan, Viktor Grünwald, David Cella, Michael DeRosa, Paul C. Nathan, Robert J. Motzer, Bryan Bennett, Scott M. Berry, Kristine Broglio
Publikováno v:
The Lancet Oncology. 17:994-1003
In the phase 3 CheckMate 025 study, previously treated patients with advanced renal cell carcinoma who were randomly assigned to nivolumab had an overall survival benefit compared with those assigned to everolimus. We aimed to compare health-related
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d091c976b65aeb108b9741f4c8fd241
https://doi.org/10.1016/s1470-2045(16)30125-5
https://doi.org/10.1016/s1470-2045(16)30125-5
Autor:
Jeffrey S. Weber, Theodore F. Logan, Elmer Berghorn, Jeffrey A. Sosman, Suresh G. Nair Md, Donald P. Lawrence, Leslie A. Fecher, Christine Horak, George Kong, Lynn M. Schuchter, Craig L. Slingluff, Geoff Gibney, Joel Jiang, F. Stephen Hodi, Elizabeth I. Buchbinder, Mary Ruisi, Ryan J. Sullivan
Publikováno v:
The Lancet. Oncology. 17(7)
Summary Background Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in patients with advanced melanoma, albeit with more high-grade adverse events. We assessed w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2363ef66cb8bf9a44e92329a4eb0d3a0
https://pubmed.ncbi.nlm.nih.gov/27733291
https://pubmed.ncbi.nlm.nih.gov/27733291